abemaciclib + ribociclib

**Abemaciclib + ribociclib** refers to a comparator group used in clinical research, specifically in a prospective, multicenter, randomized controlled trial sponsored by **Henan Cancer Hospital** (NCT06405802), rather than a single co-formulated drug product. This arm represents an investigator's choice between two approved small molecule inhibitors of **cyclin-dependent kinases 4 and 6 (CDK4/6)**: **abemaciclib** (Verzenio, developed by **Eli Lilly**) and **ribociclib** (Kisqali, developed by **Novartis**). Both agents are orally administered and are indicated for the treatment of hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer. They function by inducing G1 phase cell cycle arrest, thereby suppressing tumor cell proliferation. In the adjuvant setting, these drugs are used to reduce the risk of recurrence in high-risk patients, as established by the monarchE (abemaciclib) and NATALEE (ribociclib) trials. In the Henan Cancer Hospital study, this comparator arm serves as the active control to evaluate the tolerability and efficacy of the Chinese CDK4/6 inhibitor dalpiciclib.

Other names

Abemaciclib/Ribociclib